Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 3, 1997, Pages 553-559

  Toft, Ingrid ^a,b   Bønaa, Kaare H ^a   Ingebretsen, Ole C ^a   Nordøy, Arne ^b   Birkeland, Kåre I ^c   Jenssen, Trond ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

hypertension; insulin action; plasminogen activator inhibitor 1; waist to hip ratio

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; BODY DISTRIBUTION; BODY MASS; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; GENDER; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0030987047     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.3.553     Document Type: Article

References (16)

1. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia and coronary heart disease. Am Heart J. 1991;121:1283-1288.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
3. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia: a link between hypertension, obesity and glucose tolerance. J Clin Invest. 1985;75:809-817.
4. Byrne CD, Wareham NE, Day NE, McLeish R, Williams DRR, Hales CN. Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a subgroup of individuals with normal glucose tolerance. Diabetologia. 1995;38:1358-1366.
5. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16:207-216.
6. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
7. Hamsten A, de Faire U, Walldius G, Dahlin G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
8. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
9. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis. 1991;34:179-192.
10. Vague P, Juhan Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
11. Vague P, Juhan Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism. 1989;38:913-915.
12. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
13. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990;39:1044-1048.
14. Mykkanen L, Ronnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
15. Juhan Vague I, Thompson SG, Jespersen J for the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1873.
16. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89:321-330.